Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1158/1078-0432.CCR-13-3309 http://scihub22266oqcxt.onion/10.1158/1078-0432.CCR-13-3309 C4040316!4040316 !24727321     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24727321 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Clin+Cancer+Res 2014 ; 20 (11 ): 2846-50 Nephropedia Template TP {{tp|p=24727321 |t=2014. Aggressive variants of castration-resistant prostate cancer |pdf=|usr=}}{{24727321 }} gab.com Text Aggressive variants of castration-resistant prostate cancer JO: Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=24727321 #FOAvip A subset of patients with advanced castration-resistant prostate cancer may eventually evolve into an androgen receptor (AR)-independent phenotype, with a clinical picture associated with the development of rapidly progressive disease involving visceral sites and hormone refractoriness, often in the setting of a low or modestly rising serum prostate-specific antigen level. Biopsies performed in such patients may vary, ranging from poorly differentiated carcinomas to mixed adenocarcinoma-small cell carcinomas to pure small cell carcinomas. These aggressive tumors often demonstrate low or absent AR protein expression and, in some cases, express markers of neuroendocrine differentiation. Because tumor morphology is not always predicted by clinical behavior, the terms "anaplastic prostate cancer" or "neuroendocrine prostate cancer" have been used descriptively to describe these rapidly growing clinical features. Patients meeting clinical criteria of anaplastic prostate cancer have been shown to predict for poor prognosis, and these patients may be considered for platinum-based chemotherapy treatment regimens. Therefore, understanding variants within the spectrum of advanced prostate cancer has important diagnostic and treatment implications. Twit Text FOAVip Aggressive variants of castration-resistant prostate cancer ????Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=24727321 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24727321 #FOAvip English Wikipedia <ref>{{Cite pmid|24727321 }}</ref> Aggressive variants of castration-resistant prostate cancer #MMPMID24727321 Beltran H ; Tomlins S ; Aparicio A ; Arora V ; Rickman D ; Ayala G ; Huang J ; True L ; Gleave ME ; Soule H ; Logothetis C ; Rubin MA Clin Cancer Res 2014[Jun]; 20 (11 ): 2846-50 PMID24727321 show ga A subset of patients with advanced castration-resistant prostate cancer may eventually evolve into an androgen receptor (AR)-independent phenotype, with a clinical picture associated with the development of rapidly progressive disease involving visceral sites and hormone refractoriness, often in the setting of a low or modestly rising serum prostate-specific antigen level. Biopsies performed in such patients may vary, ranging from poorly differentiated carcinomas to mixed adenocarcinoma-small cell carcinomas to pure small cell carcinomas. These aggressive tumors often demonstrate low or absent AR protein expression and, in some cases, express markers of neuroendocrine differentiation. Because tumor morphology is not always predicted by clinical behavior, the terms "anaplastic prostate cancer" or "neuroendocrine prostate cancer" have been used descriptively to describe these rapidly growing clinical features. Patients meeting clinical criteria of anaplastic prostate cancer have been shown to predict for poor prognosis, and these patients may be considered for platinum-based chemotherapy treatment regimens. Therefore, understanding variants within the spectrum of advanced prostate cancer has important diagnostic and treatment implications. |*Carcinoma, Neuroendocrine [MESH] |*Prostatic Neoplasms, Castration-Resistant [MESH] |Humans [MESH]Aggressive variants of castration-resistant prostate cancer (epmc).pdf DeepDyve Pubget Overpricing